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Abstract
Background: Pathogenic avian influenza virus (H5N1) has the potential to cause a major global pandemic in humans. Safe
and effective vaccines that induce immunologic memory and broad heterotypic response are needed.
Methods and Findings: Healthy adults aged 18–60 and .60 years (n=313 and n=173, respectively) were randomized (1:1)
to receive two primary and one booster injection of 7.5 mgo r1 5mg doses of a subunit MF59-adjuvanted H5N1 (A/Vietnam/
1194/2004) (clade 1) vaccine. Safety was monitored until 6 months after booster. Immunogenicity was assessed by
hemagglutination inhibition (HI), single radial hemolysis (SRH) and microneutralization assays (MN). Mild injection-site pain
was the most common adverse reaction. No serious adverse events relating to the vaccine were reported. The humoral
immune responses to 7.5 mg and 15 mg doses were comparable. The rates for seroprotection (HI.40; SRH.25mm
2;M N
$40) after the primary vaccination ranged 72–87%. Six months after primary vaccination with the 7.5 mg dose, 18% and
21% of non-elderly and elderly adults were seroprotected; rates increased to 90% and 84%, respectively, after the booster
vaccination. In the 15 mg group, seroprotection rates among non-elderly and elderly adults increased from 25% and 62%
after primary vaccination to 92% and 88% after booster vaccination, respectively. A heterologous immune response to the
H5N1/turkey/Turkey/05 strain was elicited after second and booster vaccinations.
Conclusions: Both formulations of MF59-adjuvanted influenza H5N1 vaccine were well tolerated. The European Union
requirement for licensure for pre-pandemic vaccines was met by the lower dose tested. The presence of cross-reactive
antibodies to a clade 2 heterologous strain demonstrates that this vaccine may be appropriate for pre-pandemic programs.
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Introduction
The highly pathogenic avian influenza H5N1 virus, first
reported in China in 1996, is responsible for severe avian
influenza outbreaks [1–3]. The disease is now widespread among
poultry and migratory birds in many parts of the world, and more
than 380 humans have been infected, with approximately 240
(63%) deaths [4]. Based on the number of human infections, the
H5N1 virus is considered the most likely candidate to cause the
next pandemic [5], which is expected to spread quickly and result
in substantial global morbidity and mortality [6–7].
Since future pandemic virus strains cannot be clearly anticipat-
ed, vaccines using strains with pandemic potential, such as H5N1,
that induce immunologic memory and cross-reactivity, could form
the first line of defense [8]. Due to the rapid spread and significant
logistic challenges in supplying sufficient quantities of pandemic
vaccine [9,10], proactive priming of selected populations with an
H5N1 pre-pandemic vaccine should be considered now.
Immunogenicity data on conventional non-adjuvanted H5N1
vaccines are not encouraging. A previous study showed that two
vaccinations with 90 mg hemagglutinin (HA) of a non-adjuvanted
vaccine induced an antibody response at protective levels in only
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found that two 30 mg doses of an alum-adjuvanted split-virion
H5N1 vaccine were needed to induce an immune response that
met two of three criteria for European Union licensure [12]. Since
the amount of antigen in both these cases is substantially more
than is needed for protection against seasonal influenza strains,
and given current limits on worldwide vaccine production
capacity, measures to increase the immune response and reduce
the antigen content are essential. This is particularly important as
clinical trials of H5N1 vaccines have shown that two doses of
adjuvanted vaccine are necessary to satisfy all European regulatory
criteria for immunogenicity [12–14].
The use of adjuvants in vaccines is an established method for
increasing the immune response and cross-reactivity and reducing
the antigen content [15]. MF59
H is the first oil-in-water emulsion
licensed as an adjuvant for human use [15] and has been shown to
increase the immune response against homologous and heterol-
ogous interpandemic seasonal influenza vaccine strains in the
elderly [16–19] and other at-risk populations [20–22]. The safety
database for MF59 is larger and more extensive than that for any
other adjuvanted influenza vaccine.
With the exception of the virus strain and the amount of
antigen, the MF59-adjuvanted H5N1 vaccine used in this trial and
the licensed seasonal influenza vaccine, Fluad
H, are identical.
Previous clinical trials using other potential pandemic influenza
strains such as H5N3 [2,23–24] and H9N2 [25] have shown that
the addition of MF59: i) significantly increases the immunogenicity
of the H5 and H9 antigens, ii) confers cross-reactivity against
antigenically drifted strains [17,24], and iii) allows reduction of the
antigen content. This is the first study to investigate the cross-
reactivity, immunogenicity and safety of an H5N1 vaccine in both
non-elderly (aged 18–60 years) and elderly (aged.60 years) adult
populations. In this clinical trial, the humoral immune response to
two primary doses and, in a subgroup, a booster dose of a subunit
MF59-adjuvanted H5N1 influenza vaccine is reported.
Methods
Study design and objectives
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1This observer-blind, randomized study was conducted
at four sites in Italy between March 2006 and July 2007. The
primary objective was to assess the immunogenicity and safety of
up to three 0.5 mL intramuscular injections of 7.5 mgo r1 5mg
MF59-adjuvanted H5N1 vaccine according to the regulatory
guideline [26]. The study was powered for a secondary objective to
statistically distinguish between primary vaccination with the
7.5 mg and 15 mg dose.
Participants. Healthy adults 18 years of age and above were
eligibletoparticipateinthestudy.Principalcriteriaforexclusionfrom
the study were history of anaphylactic shock; allergy to eggs or any
vaccine component; immunodeficiency or immunosuppressive
therapy; participation in another clinical trial; previous receipt of
an H5N1, H3 or H9 vaccine; current acute febrile disease; current
use of antibiotics or antivirals; planned surgery during the study
period; and, for women, pregnancy or refusal to use reliable
contraception. The study was approved by the Ethics Review
Committee of each participating center and was conducted in
accordance with the principles of the Declaration of Helsinki and
Good Clinical Practice. The study is registered in the National
Institutes of Health ClinicalTrials.gov register (NCT00311480).
Written informed consent was obtained from each eligible
volunteer before enrollment.
Vaccines and randomization. Eligible participants were
randomized at a 1:1 ratio, stratified by age group, to receive two
vaccinations of either 7.5 mgo r1 5mg HA H5N1 (A/Vietnam/
1194/2004; NIBRG-14) inactivated subunit influenza virus
vaccine adjuvanted with MF59. A subgroup of the first 50% of
participants enrolled at each site also received a booster
vaccination with the same dose as that used for primary
vaccination. Both formulations were supplied in pre-filled
syringes (0.5 mL) and administered into the deltoid muscle by
an un-blinded individual who had sole access to the randomization
code at each site. All other site personnel and participants were
blinded to the vaccine group assignment. The first two
vaccinations were administered 21 days apart, and the third
(booster) vaccination was administered 6 months later.
Safety surveillance. Each participant was observed for 30
minutes post-injection for anaphylactic reactions, and was
instructed to complete a diary card on the day of vaccination
and each of the 6 subsequent days to report solicited local
reactions at the site of injection (i.e., ecchymosis, redness,
induration, swelling and pain) and systemic reactions (i.e., chills,
malaise, myalgia, arthralgia, nausea, headache, sweating, fatigue
and fever). Severe solicited reactions were defined as injection-site
reactions .50 mm diameter, reactions preventing the
performance of normal daily activities or body temperature
$40uC. All unsolicited adverse events were recorded for 3 weeks
after each vaccination and assessed by the investigator for severity,
seriousness and relationship to the study vaccine. In addition, all
adverse events necessitating a physician’s visit or leading to
premature study discontinuation, and all serious adverse events
were recorded during the 6-month follow-up periods after the
second and booster vaccinations.
Laboratory methods. Blood samples were collected from
study participants at baseline before the first vaccination, before the
second vaccination, and at 3 weeks and 6 months after the second
vaccination (pre-booster). In the booster subset, blood samples were
also collected 3 weeks and 6 months post-booster. The modified
hemagglutinin-inhibition (HI) test using horse erythrocytes was
performedinthelaboratoryofClinicalSerology,NovartisVaccines,
Marburg, Germany and was based on the method of Stephenson
andcolleagues[27].TheHItiterisexpressedasthereciprocalofthe
highest dilution at which hemagglutination was still completely
inhibited. Single radial hemolysis (SRH) was based on a modified
method of that devised by Schild and colleagues [28–29]. The
European Agency for Evaluation of Medicinal Products criterion of
serologic response to influenza vaccines, a SRH value of .25 mm
2,
was used as a cut-off for serologic protection [26].
Microneutralization (MN) was performed according to the
method previously described by Nicholson and colleagues [2].
Serial serum dilutions started at 1:20. The reciprocals of twofold
dilutions of serum that achieved 50% or greater neutralization of
virusgrowthwereconsideredpositive.Neutralizingtitersthatconfer
seroprotection against H5N1 influenza strains have not been
agreed, but we have used a titer of $40, which is in line with the
cut-off used in other studies [11–14,23]. Control sera included
human and sheep sera immunized with the influenza H5N1/
Vietnam/1194/2004 strain. SRH and MN assays were performed
using the homologousH5N1/Vietnam/1194/2004 strain(NIBRG-
14; clade 1) and also the H5N1/turkey/Turkey/1/05 (NIBRG-23;
clade 2) heterologous strain to test for cross-reactivity. Laboratory
staff were blinded to the participants’ vaccine dosages.
Statistical analyses. The planned sample size of 460
individuals (i.e., 230 subjects per study arm) was sufficient to
demonstrate that the immune response to primary vaccination
with 7.5 mg HA was non-inferior to the 15 mg HA formulation.
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sampling time point, the proportion of subjects seroprotected,
defined as an SRH area $25 mm
2 or MN titer $40, were
calculated and two-sided 95% confidence intervals (CIs) were
determined using the Clopper-Pearson method. MN titers below
the detection limit (1:20) were arbitrarily assigned to half that limit
for the purpose of the analysis. Undetectable SRH areas were
assigned an area of 4 mm
2. The immune response elicited by two
vaccinations formulated with 7.5 mg HA was considered non-
inferior to that containing 15 mg HA if the lower limit of the two-
sided 95% CI around the ratio of geometric mean titer (GMT) at
3 weeks after the second injection (GMT7.5/GMT15) exceeded
0.5. Participants were excluded from the immunogenicity analysis
if they did not receive all designated vaccinations or if the planned
blood collections were missed or performed outside the specified
time window. Safety was analyzed in participants who received at
least one vaccination and reported solicited or unsolicited adverse
events.
Results
Study population
The target was to enrol and randomize 520 subjects to
treatment, but due to slow recruitment a total of 486 individuals
were enrolled in the study, of whom 313 were 18–60 years of age
and 173 were .60 years of age (Figure 1). One participant (in the
18–60 year age cohort) presented with a transient syncopal event
and withdrew before receiving any vaccination. A total of 485
participants received the first vaccination and were therefore
included in the safety analysis, while 471 participants (97%)
Figure 1. Subject disposition. A total of 486 healthy adults were enrolled in the study and randomized in a 1:1 ratio, stratified by age group (non-
elderly adults, aged 18–60 years, and elderly adults, aged .60 years) to receive two vaccinations of either 7.5 mgo r1 5mg HA H5N1 (A/Vietnam/
1194/2004; NIBRG-14) inactivated subunit influenza virus vaccine adjuvanted with MF59. The first two vaccinations were administered 21 days apart,
and a subset of the first participants also received a third (booster) vaccination 6 months later.
doi:10.1371/journal.pone.0004384.g001
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(46%) agreed to receive a third (booster) vaccination. The booster
subset was not randomized: subjects were able to accept or decline
a booster dose, which led to small differences in numbers between
the groups. There were no major protocol deviations and,
therefore, intention-to-treat analyses are reported throughout.
Within each age group, demographic characteristics were similar
between the 7.5 mg and 15 mg groups (Table 1).
Safety analysis
Both the 7.5 mg and 15 mg formulations were well tolerated,
and there were no reports of serious adverse events related to the
study vaccine during the study period or during follow-up (mean
13 months) (Figure 2a–b). Although injection-site pain was the
most commonly reported reaction, only 2% of reported cases were
severe enough to interfere with daily activities. Other severe local
reactions occurred in less than 1% of the total population and were
of short duration. Solicited adverse reactions were more common
in adults ,60 years (Figure 2a) than in the elderly population
(Figure 2b); in both age cohorts their frequency decreased between
the first and second vaccinations and remained stable after the
third vaccination.
The most commonly reported solicited systemic adverse
reactions in both age cohorts were myalgia and headache, with
the highest rates occurring after the first vaccination (in the 7.5 mg
group: myalgia in 28% of non-elderly and 8% of elderly and
headache in 15% of non-elderly and 9% of elderly; in the 15 mg
group: myalgia in 26% non-elderly and 13% elderly and headache
in 19% non-elderly and 9% elderly). Severe solicited reactions
were reported by less than 2% of non-elderly adults and 1% of the
elderly participants (Figure 2a–b).
After primary vaccination, an axillary temperature of 38uCo r
greater was reported by 1% and 3% of non-elderly adults in the
7.5 mg and 15 mg groups, respectively, while no elderly partici-
pants reported fever. No participants reported severe fever
($40uC) and no participant of any age reported fever after the
booster vaccination. Fewer than 3% of individuals in either dose
group reported mild to moderate non-solicited adverse events that
were possibly related to the vaccine.
During the 3-week to 6-month follow-up period after the second
vaccination, fewer than 3% of participants reported adverse
events. One participant (18–60 years) in the 7.5 mg group reported
a non-solicited adverse event possibly related to vaccination
(generalized myalgia and arthralgia of moderate severity 30 days
after the second vaccination). One pregnancy occurred before the
second vaccination and the participant withdrew from the study
and subsequently delivered a healthy full-term infant.
After the third vaccination, one non-elderly adult (1%) and one
elderly (3%) participant in the 7.5 mg group and two (2%) non-
elderly adults and one (4%) elderly participant in the 15 mg group
reported non-solicited adverse events, all judged as unrelated to
the study vaccine, during the 3-week to 6-month follow-up period.
No vaccine-related serious adverse events were reported during
the entire study period.
Immunogenicity
A total of 466 of the 486 enrolled individuals were included in
the immunogenicity analyses.
i) Primary vaccination. At baseline in both dose groups, HI
titers, SRH areas and MN titers, respectively, were detectable in
0–3%, 5–9% and 3% of non-elderly adults and 11–12%, 11–24%
and 15–18% of elderly participants (Tables 2, 3, 4). Elderly
subjects had higher baseline antibody titers to H5N1 than younger
adults. Antibody responses against H5N1 were already observed in
both vaccine groups 21 days after the first vaccination, as
demonstrated by HI, SRH and MN assays (Table 2, 3, 4). After
the second vaccination, geometric mean ratios (GMRs) were
comparable or higher in the 7.5 mg group than in the 15 mg group
and also higher in non-elderly adults than in the elderly.
Following two vaccinations with either formulation, 81–86% of
non-elderly adults and 76–79% of elderly adults had neutralizing
antibody titers of at least 40 (Figure 3a,b), and this increased to 94–
96% of non-elderly adults and 96–97% of elderly adults after the
booster vaccination (Figure 3c,d). These percentages were
comparable with those for seroprotection rates assessed by HI
and SRH (Table 2 and 3), with good Pearson correlation on log10-
transformed titers between the assays across injection, age group
and formulation (r=0.67).
After primary vaccination (two-dose regimen) both the 7.5 mg
and the 15 mg MF59-adjuvanted vaccine formulations met all the
Committee for Medicinal Products for Human Use criteria for
evaluation of influenza vaccines (HI and SRH assays) in both non-
elderly and elderly participants [26].
ii) Booster vaccination. Seroprotection rates assessed by HI
assay increased from 27% (18–60 years) and 54% (.60 years)
immediately before the 7.5 mg booster dose to 83% and 92%,
respectively, 3 weeks following the booster dose. Similar increases
in seroprotection rates were observed in the 15 mg group, rising
from 34% (18–60 years) and 62% (.60 years) before the booster
dose to 76% and 96%, respectively, after the booster dose
(Table 2). Similarly, seroprotection rates assessed by SRH
increased from 18% (18–60 years) and 21% (.60 years)
immediately before the 7.5 mg booster to 89% and 84%,
respectively, 3 weeks following the booster (Table 3). Similar
increases in seroprotection rates were observed in the 15 mg group,
Table 1. Age, sex and ethnic origin distribution across groups
18–60 years .60 years
7.5 mgH A 1 5mgH A 7 . 5mgH A 1 5mgH A
Number randomized 157 156 87 86
Age, years Mean (range) 43.4 (18–60) 42.3 (18–60) 71 (62–88) 70.1 (61–90)
Ethnic origin Caucasian, % 99 97 100 100
Gender Male: Female, % 45:55 45:55 60:40 56:44
Previous influenza vaccination, % 52 56 89 85
HA, hemagglutinin
doi:10.1371/journal.pone.0004384.t001
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those aged 18–60 years and .60 years, respectively. MN titers in
non-elderly and elderly recipients increased from 41% to 94% and
from 42% to 97%, respectively, after the 7.5 mg booster and from
53% to 96% and from 69% to 96%, respectively, after the 15 mg
booster (Table 4).
Figure 2. Most commonly reported solicited systemic adverse reactions. Classified as mild/moderate (white bars) or severe (grey bars) after
the first, second and third vaccination in non-elderly adults (18–60 years; part a) and in elderly adults (.60 years; part b).
doi:10.1371/journal.pone.0004384.g002
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An antibody response against a heterologous clade 2 strain
(H5N1/turkey/Turkey/1/05) was detectable by HI assay, with
cross-immunogenicity to the clade 2 strain increasing from 28–
36% after the second dose to 59–70% after the third dose, across
dosage groups and age cohorts. Seroprotection rates as measured
by SRH were 57–77% and 78–88% after the second and third
doses, respectively. The MN GMTs ranged 12–19 after the second
vaccination and 44–93 after the booster for the clade 2 strain
(Table 5), versus 80–117 and 154–225 for the clade 1 strain
(Table 4) across formulations and age cohorts. SRH GMAs were
15–24 and 24–34 for clade 2 (Table 5) versus 30–37 and 32–42 for
the clade 1 strain after primary and booster vaccination (Table 3).
Discussion
The H5N1 virus is the most likely candidate for an emerging
pandemic strain. Owing to the anticipated rapid spread of the
pandemic virus, together with the time required to produce a
vaccine that matches the circulating strain, the first wave of the
pandemic may have passed in many countries before a significant
amount of pandemic vaccine is available. The success of national
pandemic preparedness strategies may depend on providing
appropriate H5N1 pre-pandemic vaccines (i) in a proactive
controlled manner (ii) that induce immunologic memory and
demonstrate cross-reactivity in the whole population, including the
elderly, and (iii) with a proven safety profile. Evidence for the
safety of the MF59 adjuvant is provided not only by the present
trial, but also from a review of the database (.14,000 clinical trial
participants and .30 million distributed doses post-licensure) for
the interpandemic influenza vaccine Fluad
H, which differs from the
H5N1 vaccine only in its HA content and viral strain composition
(267.5 mgo r2 615 mg H5N1 versus 1645 mg HA seasonal viral
strains). It has been well established that repeated yearly
vaccination with Fluad
H does not lead to increased reactogenicity
or other side effects [30], and the post-marketing MF59 safety
database showed no increase in spontaneous reports of adverse
events compared with conventional influenza vaccines. While little
is published on immunopotentiators for pre-pandemic vaccines, a
recent study of an H5N1 vaccine using a novel adjuvant in non-
elderly adults [13] indicates a comparable immune response to
that obtained with MF59. However, the novel adjuvant appeared
to result in a higher incidence of mild to moderate injection-site
pain [13]. In contrast, in the current study both 7.5 mg and 15 mg
doses of MF59-adjuvanted H5N1 vaccine were equally well
tolerated and induced neutralizing antibody responses in non-
Table 2. Hemagglutination inhibition response: MF59-adjuvanted H5N1 subunit influenza vaccine formulations and age cohort
18–60 years .60 years
7.5 mgH A 1 5mgH A 7 . 5mgH A 1 5mgH A
n=151 n=147 n=81 n=74
Baseline
GMT 5.1 (4.8–5.4) 5.5 (5.2–5.9) 8.1 (6.3–11) 8.2 (6.3–11)
Seroprotection rate, % 0 (0–2) 3 (1–7) 12 (6–22) 11(5–20)
3 weeks after first vaccination
GMT 17 (13–23) 21 (16–28) 31 (20–49) 40 (25–63)
GMR 3.4 (2.6–4.5) 3.8 (2.8–5.0) 3.9 (2.6–5.7) 4.9 (3.3–7.3)
Seroprotection rate, % 34 (26–42) 39 (31–47) 51 (39–62) 53 (41–64)
Seroconversion rate, % 34 (26–42) 35 (28–44) 38 (28–50) 46 (34–58)
3 weeks after second vaccination
GMT 82 (62–110) 85 (64–110) 77 (53–114) 82 (55–123)
GMR 16 (12–21) 15 (12–21) 9.52 (6.6–1.4) 10 (6.8–1.5)
Seroprotection rate, % 73 (65–80) 72 (64–79) 75 (64–84) 76(64–85)
Seroconversion rate, % 73 (65–80) 69 (61–77) 67 (55–77) 70 (59–80)
Pre-booster (subset) n=71 n=82 n=37 n=26
GMT 12 (9.0–17) 16 (12–21) 26 (13–49) 42 (21–85)
Seroprotection rate, % 27 (17–39) 34 (24–45) 54 (37–71) 62 (41–80)
3 weeks post-booster
GMT 138 (93–205) 104 (72–151) 129 (83–201) 212 (130–345)
GMR to pre-booster 11 (7.6–16) 6.54 (4.6–9.3) 5.02 (2.8–9.0) 5.07 (237–9.6)
Seroprotection rate, % 83 (72–91) 76 (65–84) 92 (78–98) 96 (80–100)
Seroconversion rate, % 73 (61–83) 62 (51–73) 51 (34–68) 54 (33–73)
6 months post-booster n=69 n=76 n=35 n=22
GMT 27 (18–41) 29 (20–42) 36 (20–68) 71 (34–145)
Seroprotection rate, % 52 (40–64) 46 (35–58) 57 (39–74) 77 (55–92)
Numbers in parenthesis are two-sided 95% confidence intervals; Seroprotection=HI titer $40; Seroconversion=negative pre-vaccination serum (i.e., HI titer ,10) and
post-vaccination HI titer $40 or significant increase (at least a fourfold increase in HI titer in subjects who were positive pre-vaccination, i.e., HI titer $10); HA,
hemagglutinin; GMT, geometric mean titer; GMR, the geometric mean of the ratio over baseline.
doi:10.1371/journal.pone.0004384.t002
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vaccine beyond the 6-month follow-up period of this study are in
progress.
As was the case in previous H5N1 vaccine trials [11–14], some
of our study participants were not immunologically naı ¨ve at
baseline. The microneutralization results in the 18–60 year age
group are consistent with findings from earlier studies indicating
that approximately 1–3% of subjects have H5N1 antibody at
baseline [11–14]. The higher incidence of H5N1 antibodies in the
elderly may reflect increased natural exposure or seasonal
vaccination (in particular, the H1N1 component). Others have
shown that approximately 34% of recipients of seasonal influenza
vaccine have cross-reactive neutralizing antibody to H5N1 [31].
Since immune responses in baseline seronegative participants were
similar to those in the population as a whole, the inclusion of a
small number of baseline seropositive individuals does not affect
the interpretation of the results.
Regardless of antigen content, the good immune response
observed after two primary injections of adjuvanted H5N1 vaccine
exceeded all requirements of the European Regulatory Authority
[26]. More than 76% of the individuals were seroprotected or
achieved an MN titer $40. Although correlates of protection for
MN titers against H5N1 virus infections remain unknown,
neutralizing antibody titers $40 are increasingly recognized as
protective [11–13]. The proportion of younger adults (,60 years)
with neutralizing antibody titers $40 after the second 7.5 mg
H5N1 vaccination compared favorably with figures reported in
studies using up to 90 mg of non-adjuvanted [11] or 30 mgo f
aluminum-adjuvanted H5N1 vaccine in individuals aged 18–
40 years [12].
As expected, seroprotection rates fell significantly 6 months
after primary vaccination but increased after the booster dose to
levels higher than those achieved 3 weeks after the second
vaccination, indicating a memory response in both elderly and
non-elderly adults. As the timing of the next pandemic influenza
outbreak is unknown, the memory response may be more
important than persistence, as subsequent exposure to the
pandemic vaccine or wild-type virus could trigger a full
immunologic response.
A heterologous immune response against H5N1/turkey/
Turkey/1/05 (NIBRG-23) was detectable after the primary and
booster vaccinations, indicating that there is cross-reactivity
between the clade 1 and clade 2 strains. Increased heterologous
immune responsiveness against antigenically drifted strains
presents a significant public health advantage in the event of a
pandemic outbreak. We have shown elsewhere that, among
primed subjects, protective cross-reactive antibody titers to diverse
H5N1 virus variants can be achieved within 7 days after
Table 3. Single radial hemolysis (SRH) response: MF59-adjuvanted H5N1 subunit influenza vaccine formulations and age cohort
18–60 years .60 years
7.5 mg HA n=149 15 mg HA n=149 7.5 mgH An=8 4 1 5mgH An=8 0
Baseline
GMA 4.8 (4.325.3) 5.2 (4.725.8) 6.0 (4.927.4) 7.6 (6.229.5)
Seroprotection rate, % 5 (2210) 9 (5214) 11 (5219) 24 (15235)
3 weeks after first vaccination
GMA 11 (9.5214) 15 (12218) 17 (13222) 19 (14225)
GMR 2.4 (2.022.9) 2.8 (2.423.4) 2.9 (2.223.7) 2.5 (1.923.2)
Seroprotection rate, % 40 (32249) 51 (43259) 52 (41263) 58 (46268)
Seroconversion rate, % 38 (30–47) 42 (34–51) 44 (33–55) 43 (32–54)
3 weeks after second vaccination
GMA 37 (32243) 36 (31241) 30 (24237) 31 (25239)
GMR 7.7 (6.629.1) 6.9 (5.928.0) 5.0 (3.926.4) 4.1 (3.225.3)
Seroprotection rate, % 85 (79291) 85 (79291) 80 (70288) 81 (71289)
Seroconversion rate, % 85 (78–90) 80 (73–86) 70 (59–80) 69 (57–79)
Pre-booster (subset) n=71 n=83 n=38 n=26
GMA 6.8 (5.428.6) 8.0 (6.529.9) 6.3 (4.329.1) 16 (10224)
Seroprotection rate, % 18 (10229) 25 (16236) 21 (10237) 62 (41280)
3 weeks post-booster
GMA 41 (34248) 42 (36249) 32 (23246) 42 (29262)
GMR to pre-booster 6.0 (4.727.5) 5.2 (4.226.5) 5.2 (3.527.7) 2.7 (1.724.2)
Seroprotection rate, % 89 (79295) 92 (83297) 84 (69294) 88 (70298)
Seroconversion rate, % 83 (72–91) 81 (71–89) 63 (46–78) 65 (44–83)
6 months post-booster n=69 n=76 n=35 n=22
GMA 17 (13221) 17 (14221) 13 (8.4219) 25 (16239)
Seroprotection rate, % 55 (43267) 55 (43267) 43 (26261) 77 (55292)
Numbers in parenthesis are two-sided 95% confidence intervals; Seroprotection=SRH $25mm
2; Seroconversion=negative pre-vaccination serum (i.e., SRH titer #
4mm
2) and post-vaccination SRH area $25 mm
2 or significant increase (at least a 50% increase in SRH area in subjects who were positive pre-vaccination, i.e., SRH area
.4mm
2); HA, hemagglutinin; GMA, geometric mean area; GMR, the geometric mean of the ratio over baseline
doi:10.1371/journal.pone.0004384.t003
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18–60 years .60 years
7.5 mg HA n=151 15 mg HA n=151 7.5 mgH An=8 4 1 5mgH An=8 0
Baseline
GMT 11 (10212) 11 (10212) 18 (14222) 16 (13220)
MN $1:40, % 3 (127) 3 (127) 18 (10228) 15 (8225)
3 weeks after first vaccination
GMT 26 (22232) 35 (29242) 42 (31259) 51 (37–71)
MN $1:40, % 33 (26241) 44 (36252) 49 (38260) 51 (40263)
3 weeks after second vaccination
GMT 117 (982140) 102 (852122) 80 (612105) 90 (682119)
MN $1:40, % 85 (78290) 81 (74287) 79 (68287) 76 (65285)
Pre-booster (subset) n=71 n=83 n=38 n=26
GMT 33 (26242) 43 (34254) 31 (20247) 63 (392101)
MN $1:40, % 41 (29253) 53 (42264) 42 (26259) 69 (48286)
3 weeks post-booster
GMT 210 (1682262) 214 (1742263) 154 (1052227) 225 (1462345)
MN $1:40, % 94 (86298) 96 (90299) 97 (862100) 96 (802100)
6 months post-booster n=69 n=76 n=35 n=22
GMT 34 (26244) 35 (27244) 25 (17239) 46 (28275)
MN $1:40, % 41 (29253) 46 (35258) 37 (21255) 64 (41283)
Numbers in parenthesis are two-sided 95% confidence intervals; HA, hemagglutinin; GMT, geometric mean titer
doi:10.1371/journal.pone.0004384.t004
Figure 3. Reverse cumulative distribution curves for microneutralization antibody titers. Measured 3 weeks after a second injection and
3 weeks after a booster dose in non-elderly adults (18–60 years; parts a and c, respectively) and in elderly adults (.60 years; parts b and d,
respectively).
doi:10.1371/journal.pone.0004384.g003
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[Stephenson, manuscript submitted]. In addition, the availability
of a 7.5 mg formulation of MF59-adjuvanted influenza vaccine
would allow a threefold increase in the number of subjects who
could be vaccinated compared with seasonal trivalent influenza
vaccines, enabling production of higher quantities of vaccine, in
pre-pandemic and pandemic situations, as encouraged by the
World Health Organization [32].
In conclusion, H5N1/Vietnam/1194/2004 influenza vaccine
adjuvanted with MF59 can be safely used as a pre-pandemic
vaccine. Primary vaccination of non-elderly and elderly adults
induces a sufficient immune response and cross-reactivity against
the clade 2 H5N1/turkey/Turkey/05 strain, and booster
vaccination leads to a strong and sustained immunologic response.
A low-dose antigen formulation (7.5 mg) resulted in a comparable
seroprotection benefit when compared with a higher dose (15 mg).
These results, in conjunction with the extensive safety data on the
MF59 adjuvant, suggest that this vaccine would be a suitable
choice for proactive priming in advance of pandemic influenza.
Supporting Information
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Found at: doi:10.1371/journal.pone.0004384.s001 (0.25 MB
PDF)
Checklist S1 CONSORT checklist
Found at: doi:10.1371/journal.pone.0004384.s002 (0.06 MB
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Table 5. Heterologous response (A/turkey/Turkey/1/05 2 NIBRG-23) following immunisation with MF59-adjuvanted H5N1 subunit
influenza vaccine
Assessment
Parameter 7.5 mgH A 1 5mgH A
Adult HI n=70 n=79
Post-second injection (day 43) GMT 18 (13–24) (n=69) 14 (10–19) (n=78)
Seroprotection rate % 36 (25–49) 28 (19–40)
Post-booster injection (day 223) GMT 58 (39–86) 46 (31–67)
Seroprotection rate % 70 (58–80) 59 (48–70)
MN n=70 n=81
Post-second injection (day 43) GMT 19 (15–24) 19 (15–24)
Titer $40 % 27 (17–39) 21 (13–31)
Post-booster injection (day 223) GMT 77 (60–100) 93 (74–118)
Titer $40 % 73 (61–83) 79 (69–87)
SRH n=70 n=81
Post-second injection (day 43) GMA 23 (19–28) 24 (20–28)
Seroprotection rate % 70 (58–80) 70 (59–80)
Post-booster injection (day 223) GMA 30 (26–36) 34 (29–39)
Seroprotection rate % 83 (72–91) 88 (78–94)
Elderly HI n=36 n=26
Post-second injection (day 43) GMT 14 (8.4–22) 13 (7.74–23) (N=23)
Seroprotection rate % 36 (21–54) 35 (16–57)
Post-booster injection (day 223) GMT 36 (19–68) 49 (25–97)
Seroprotection rate % 67 (49–81) 65 (44–83)
MN n=37 n=26
Post-second injection (day 43) GMT 12 (9.4–16) 17 (13–23)
Titer $40 % 11 (3–25) 31 (14–52)
Post-booster injection (day 223) GMT 44 (29–67) 61 (39–95)
Titer $40 % 62 (45–78) 65 (44–83)
SRH n=37 n=26
Post-second injection (day 43) GMA 15 (9.91–22) 24 (16–36)
Seroprotection rate % 57 (39–73) 77 (56–91)
Post-booster injection (day 223) GMA 24 (17–34) 33 (23–48)
Seroprotection rate % 78 (62–90) 88 (70–98)
Numbers in parenthesis are two-sided 95% confidence intervals; GMT/GMA, geometric mean titer/geometric mean area ;Seroprotection rate=SRH $25mm
2 or MN
$40.
doi:10.1371/journal.pone.0004384.t005
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